Kevin Michael Krause An2 Therapeutics, Inc. (ANTX) insider trading activity

ANTX Quotes by TradingView

Kevin Michael Krause is Chief Strategy Officer of AN2 Therapeutics, Inc.. Currently has a direct ownership of 31,914 shares of ANTX, which is worth approximately $45,956. The most recent transaction as insider was on Mar 15, 2024, when has been sold 30,000 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 31.9K
0% 3M change
n/a 12M change
Total Value Held $45,956

Kevin Michael Krause Transaction History

Date Transaction Value Shares Traded Shares Held Form
Mar 15 2024
BUY
Grant, award, or other acquisition
-
30,000 Added 48.45%
31,914 Common Stock
Jan 09 2024
SELL
Open market or private sale
$149,378 $20.14 p/Share
7,417 Reduced 79.49%
1,914 Common Stock
Jan 09 2024
BUY
Exercise of conversion of derivative security
$26,033 $3.51 p/Share
7,417 Added 44.29%
9,331 Common Stock
Jan 02 2024
SELL
Open market or private sale
$51,969 $20.12 p/Share
2,583 Reduced 57.44%
1,914 Common Stock
Jan 02 2024
BUY
Exercise of conversion of derivative security
$1,084 $0.42 p/Share
2,583 Added 36.48%
4,497 Common Stock
KMK

Kevin Michael Krause

Chief Strategy Officer
Menlo Park, CA

Track Institutional and Insider Activities on ANTX

Follow AN2 Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ANTX shares.

Notify only if

Insider Trading

Get notified when an An2 Therapeutics, Inc. insider buys or sells ANTX shares.

Notify only if

News

Receive news related to AN2 Therapeutics, Inc.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on ANTX